<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312436858</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312436858</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Functional single-nucleotide polymorphisms in the <italic>DEFB1</italic> gene are associated with systemic lupus erythematosus in Southern Brazilians</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sandrin-Garcia</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436858">1</xref>
<xref ref-type="aff" rid="aff2-0961203312436858">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brandão</surname><given-names>LAC</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436858">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Guimarães</surname><given-names>RL</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436858">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pancoto</surname><given-names>JAT</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312436858">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Donadi</surname><given-names>EA</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312436858">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lima-Filho</surname><given-names>JL de</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436858">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Segat</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312436858">4</xref>
<xref ref-type="corresp" rid="corresp1-0961203312436858"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Crovella</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff5-0961203312436858">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312436858"><label>1</label>Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco, Recife, Pernambuco, Brazil</aff>
<aff id="aff2-0961203312436858"><label>2</label>Department of Genetics, Federal University of Pernambuco, Recife, Pernambuco, Brazil</aff>
<aff id="aff3-0961203312436858"><label>3</label>Department of Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil</aff>
<aff id="aff4-0961203312436858"><label>4</label>Institute for Maternal and Child Health - IRCCS ‘Burlo Garofolo’, Trieste, Italy</aff>
<aff id="aff5-0961203312436858"><label>5</label>Institute for Maternal and Child Health - IRCCS ‘Burlo Garofolo’, University of Trieste, Italy</aff>
<author-notes>
<corresp id="corresp1-0961203312436858">Ludovica Segat, Genetic Service, IRCCS Burlo Garofolo, Via dell’Istria 65/1, 34137 Trieste, Italy Email: <email>segat@burlo.trieste.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>625</fpage>
<lpage>631</lpage>
<history>
<date date-type="received"><day>10</day><month>8</month><year>2011</year></date>
<date date-type="accepted"><day>30</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Systemic lupus erythematosus (SLE) is an autoimmune disease that results in inflammation and tissue damage. The etiology of SLE remains unknown, but recent studies have shown that the innate immune system may have a role in SLE pathogenesis through the secretion of small cationic peptides named defensins. The aim of the study was to determine the possible involvement in SLE of three functional single nucleotide polymorphisms (SNPs) (c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A) in the 5’UTR region of <italic>DEFB1</italic> gene, by analyzing them in a population of 139 SLE patients and 288 healthy controls. The c.−52G&gt;A SNP showed significant differences in allele and genotype frequency distribution between SLE patients and controls (<italic>p = </italic>0.01 and <italic>p = </italic>0.02 respectively) indicating protection against SLE (A allele, OR = 0.68, AA genotype OR = 0.51). Significant differences were also observed for c.−44C&gt;G SNP, the C/G genotype being associated with susceptibility to SLE (OR = 1.60, <italic>p = </italic>0.04). Moreover<italic>,</italic> statistically significant differences between patients and controls were found for two <italic>DEFB1</italic> haplotypes (GCA and GGG, <italic>p = </italic>0.01 and <italic>p = </italic>0.02 respectively). When considering <italic>DEFB1</italic> SNPs and SLE clinical and laboratory manifestations, significant association was found with neuropsychiatric disorders, immunological alterations and anti-DNA antibodies. In conclusion, our results evidence a possible role for the c.−52G&gt;A and c.−44C&gt;G <italic>DEFB1</italic> polymorphisms in SLE pathogenesis, that can be considered as possible risk factors for development of disease and disease-related clinical manifestations. Additional studies are needed, to corroborate these results as well as functional studies to understand the biological role of these SNPs in the pathogenesis of SLE.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>SNPs</kwd>
<kwd>DEFB1</kwd>
<kwd>genetic polymorphisms</kwd>
<kwd>defensins</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312436858" sec-type="intro"><title>Introduction</title>
<p>SLE is a systemic autoimmune disease that results from deregulation of the immune response. The most frequently affected organs are joints, skin, blood cells, kidneys, serosa and the nervous system.<sup><xref ref-type="bibr" rid="bibr1-0961203312436858">1</xref></sup> The precise etiology for SLE is not known, but hormonal, genetic, viral and environmental factors may be involved.<sup><xref ref-type="bibr" rid="bibr2-0961203312436858">2</xref></sup> SLE is characterized by the production of innumerable autoantibodies due to the impaired function of B and T cells. However, the main pathways evoking this impaired immune cell function remain unknown.<sup><xref ref-type="bibr" rid="bibr3-0961203312436858">3</xref></sup> Recent studies have shown the importance of the innate immune system on SLE pathogenesis. In fact, innate immunity could confer a protection against pathogens and multicellular organisms through the secretion of broad-spectrum antimicrobial substances called defensins,<sup><xref ref-type="bibr" rid="bibr2-0961203312436858">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203312436858">3</xref></sup> possibly playing an important function in the development and course of the disease.<sup><xref ref-type="bibr" rid="bibr3-0961203312436858">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203312436858">4</xref></sup> Defensins act as the first line of defense and amplify the innate and adaptive immune responses, such as activation of mast cells, interleukin and tumor necrosis factor production, maturation of dendritic cells and memory T cells.<sup><xref ref-type="bibr" rid="bibr3-0961203312436858">3</xref>,<xref ref-type="bibr" rid="bibr5-0961203312436858">5</xref></sup></p>
<p>The <italic>DEFB1</italic> gene (8p23.1–23.2), covering approximately 8 kb and spanning along two exons, encodes the human β-defensin-1 (hBD-1). <italic>DEFB1</italic><sup><xref ref-type="bibr" rid="bibr6-0961203312436858">6</xref></sup> is constitutively expressed, but three single-nucleotide polymorphisms (SNPs), namely c.−52 G&gt;A (rs1799946), c.−44C&gt;G (rs1800972), and c.−20G&gt;A (rs11362) at the 5’ untranslated region (UTR) of <italic>DEFB1</italic> have been reported to cause functional variations in the expression of this gene.<sup><xref ref-type="bibr" rid="bibr7-0961203312436858">7</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr9-0961203312436858">9</xref></sup></p>
<p>In our study, we analyzed the distribution of these three <italic>DEFB1</italic> SNPs in SLE patients and healthy controls from Southern Brazil to investigate their association with the susceptibility and clinical features of the disease.</p></sec>
<sec id="sec2-0961203312436858" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203312436858" sec-type="subjects"><title>Patients and controls</title>
<p>DNA samples were obtained from 139 SLE patients (131 females and 8 males) aged between 17 and 67 years (mean = 39.8 ± SD = 11.6), followed-up at the Division of Clinical Immunology, University Hospital of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil. SLE diagnosis was performed according to the American College of Rheumatology Classification Criteria (ACR, 1997). A written informed consent was obtained from all individuals after the local Ethics Committee approved the protocol of this study (#2234/2007).</p>
<p>Patients were classified as European or African-derived according to phenotypic characteristics of individuals and ethnicity data of parents/grandparents reported by the participants completing an appropriate questionnaire. The question used for skin color was based on classification criteria that are used in Brazil, is well documented, and has already been considered in previous studies,<sup><xref ref-type="bibr" rid="bibr10-0961203312436858">10</xref></sup> one of which was performed on lupus patients.<sup><xref ref-type="bibr" rid="bibr11-0961203312436858">11</xref></sup></p>
<p>All clinical and laboratory information regarding the SLE patients is shown in <xref ref-type="table" rid="table1-0961203312436858">Table 1</xref>: photosensitivity, serositis (pleuritis, pericarditis), arthritis, cutaneous alterations (malar or discoid rashes, oral ulcers), neuropsychiatric disorders, nephritic disorders, antiphospholipid syndrome (APS), Raynaud’s phenomenon, Sjogren’s syndrome, hematological alterations (hemolytic anemia, leucopenia, lymphopenia, thrombocytopenia), immunological alterations (anticardiolipin, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB, and VDRL), presence of antinuclear antibodies (ANA), and presence of anti-double-strand DNA antibody (anti ds-DNA).
<table-wrap id="table1-0961203312436858" position="float"><label>Table 1</label><caption><p>Clinical and laboratory characteristics of the 139 Brazilian SLE patients studied</p></caption>
<graphic alternate-form-of="table1-0961203312436858" xlink:href="10.1177_0961203312436858-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Clinical and laboratory characteristics</th>
<th>SLE patients <italic>n</italic> (%)</th></tr></thead>
<tbody align="left">
<tr>
<td>Photosensitivity</td>
<td>40 (34.7%)</td></tr>
<tr>
<td>Serositis</td>
<td>35 (25.2%)</td></tr>
<tr>
<td>Arthritis</td>
<td>59 (42.4%)</td></tr>
<tr>
<td>Cutaneous alterations</td>
<td>83 (59.7%)</td></tr>
<tr>
<td>Neuropsychiatric disorder</td>
<td>26 (18.7%)</td></tr>
<tr>
<td>Nephritic disorder</td>
<td>77 (55.4%)</td></tr>
<tr>
<td>Hematological alterations</td>
<td>76 (54.7%)</td></tr>
<tr>
<td>Immunological alterations</td>
<td>84 (60.4%)</td></tr>
<tr>
<td>Antinuclear factor positive (ANF)</td>
<td>111 (79.8%)</td></tr>
<tr>
<td>Antibody anti-DNA (anti ds-DNA)</td>
<td>27 (19.4%)</td></tr>
<tr>
<td>Antiphospholipid syndrome (APS)</td>
<td>28 (20.1%)</td></tr>
<tr>
<td>Sjogren’s syndrome</td>
<td>4 (2.9%)</td></tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>7 (5%)</td></tr>
</tbody>
</table>
</table-wrap></p>
<p>DNA samples from 288 healthy controls (mean age = 30.1 ± SD = 9.8) without a previous family history of autoimmune disorders were obtained. All the healthy controls were blood donors and completed a questionnaire reporting the absence of autoimmune disorders (such as type 1 diabetes, autoimmune thyroiditis, celiac disease, etc.). Moreover, all controls had been previously genotyped for human leukocyte antigen (HLA) haplotypes DR3 DR4, DQ2, and DQ8 associated with an increased risk for type 1 diabetes, celiac disease and autoimmune thyroiditis. The presence of any of HLA risk haplotype was an exclusion criterion.</p></sec>
<sec id="sec4-0961203312436858"><title>DEFB1 gene sequencing</title>
<p>The SNPs in the 5’UTR region of <italic>DEFB1</italic> c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A (NCBI accession number rs1799946, rs1800972 and rs11362, respectively) were sequenced as previously described.<sup><xref ref-type="bibr" rid="bibr12-0961203312436858">12</xref>,<xref ref-type="bibr" rid="bibr13-0961203312436858">13</xref></sup> Sequencing reactions were run on the ABI 3130 genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The sequences were handled with the 4Peaks software (<ext-link ext-link-type="uri" xlink:href="http://mekentosj.com/science/4peaks/">http://mekentosj.com/science/4peaks/</ext-link>).</p></sec>
<sec id="sec5-0961203312436858"><title>Statistical analysis</title>
<p>Allele and genotype frequencies were calculated by direct gene counting and the exact Fisher’s test was used for all comparisons. Fisher’s exact test, odds ratio (OR) and 95% confidence intervals (95% CI) and adherence to the Hardy–Weinberg equilibrium were evaluated using the R statistical environment version 2.10.0 (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>). Haplotype data were obtained using the Haploview version 4.2 software.<sup><xref ref-type="bibr" rid="bibr14-0961203312436858">14</xref></sup> Genotype associations with clinical and laboratory features were performed using the EpiInfo version 3.5.1 software (<ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/epiinfo/about.htm">http://www.cdc.gov/epiinfo/about.htm</ext-link>).</p>
<p>Power analysis was performed using the post-hoc test ‘G * Power’ software (version 3.1.2) based on minor allele frequency and odds ratio (OR) (Fisher exact-test) with an alpha error of 0.05.<sup><xref ref-type="bibr" rid="bibr15-0961203312436858">15</xref></sup></p></sec></sec>
<sec id="sec6-0961203312436858" sec-type="results"><title>Results</title>
<p>The three functional SNPs c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A in the <italic>DEFB1</italic> gene were screened in 139 patients with SLE and 288 healthy controls from Southern Brazil. Allelic and genotype frequencies of the studied SNPs are shown in <xref ref-type="table" rid="table2-0961203312436858">Table 2</xref>. Genotype distributions for all three SNPs were in Hardy–Weinberg equilibrium in both patients and controls.
<table-wrap id="table2-0961203312436858" position="float"><label>Table 2</label><caption><p>Allele and genotype frequencies of 5’UTR<italic> DEFB1</italic> gene polymorphisms in SLE patients and healthy controls. <italic>P</italic>-values, odds ratio (OR) and 95% confidence intervals (CI) are also reported</p></caption>
<graphic alternate-form-of="table2-0961203312436858" xlink:href="10.1177_0961203312436858-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>SNPs</th>
<th>SLE patients (<italic>n</italic> = 139)</th>
<th>Controls (<italic>n</italic> = 288)</th>
<th>OR, 95%CI and <italic>p</italic>-values</th></tr></thead>
<tbody align="left">
<tr>
<td>−52G&gt;A</td>
<td colspan="3"/></tr>
<tr>
<td> G</td>
<td>176/278 (63.3%)</td>
<td>312/576 (54.2%)</td>
<td>OR = 1</td></tr>
<tr>
<td> A</td>
<td>102/278 (36.7%)</td>
<td>264/576 (45.8%)</td>
<td>OR = 0.68, CI 0.50–0.92, <italic>p</italic> = 0.01<xref ref-type="table-fn" rid="table-fn1-0961203312436858">*</xref></td></tr>
<tr>
<td> G/G</td>
<td>59/139 (42.5%)</td>
<td>90/288 (31.3%)</td>
<td>OR = 1</td></tr>
<tr>
<td> G/A</td>
<td>58/139 (41.7%)</td>
<td>132/288 (45.8%)</td>
<td>OR = 0.67, CI 0.42–1.08, <italic>p</italic> = 0.08</td></tr>
<tr>
<td> A/A</td>
<td>22/139 (15.8%)</td>
<td>66/288 (22.9%)</td>
<td>OR = 0.51, CI 0.27–0.94, <italic>p</italic> = 0.02<xref ref-type="table-fn" rid="table-fn1-0961203312436858">*</xref></td></tr>
<tr>
<td>−44C&gt;G</td>
<td colspan="3"/></tr>
<tr>
<td> C</td>
<td>225/278 (80.9%)</td>
<td>490/576 (85.1%)</td>
<td>OR = 1</td></tr>
<tr>
<td> G</td>
<td>53/278 (19.1%)</td>
<td>86/576 (14.9%)</td>
<td>OR = 1.34, CI 0.90–1.98, <italic>p</italic> = 0.13</td></tr>
<tr>
<td> C/C</td>
<td>90/139 (64.7%)</td>
<td>212/288 (73.6%)</td>
<td>OR = 1</td></tr>
<tr>
<td> C/G</td>
<td>45/139 (32.4%)</td>
<td>66/288 (22.9%)</td>
<td>OR = 1.60, CI 0.99–2.58, <italic>p</italic> = 0.04<xref ref-type="table-fn" rid="table-fn1-0961203312436858">*</xref></td></tr>
<tr>
<td> G/G</td>
<td>4/139 (2.9%)</td>
<td>10/288 (3.5%)</td>
<td>OR = 0.94, CI 0.21–3.37, <italic>p</italic> = 1</td></tr>
<tr>
<td>−20G&gt;A</td>
<td colspan="3"/></tr>
<tr>
<td> G</td>
<td>157/278 (56.5%)</td>
<td>364/576 (63.2%)</td>
<td>OR = 1</td></tr>
<tr>
<td> A</td>
<td>121/278 (43.5%)</td>
<td>212/576 (36.8%)</td>
<td>OR = 1.32, CI 0.98–1.79 <italic>p</italic> = 0.06</td></tr>
<tr>
<td> G/G</td>
<td>43/139 (30.9%)</td>
<td>115/288 (39.9%)</td>
<td>OR = 1</td></tr>
<tr>
<td> G/A</td>
<td>71/139 (51.1%)</td>
<td>134/288 (46.6%)</td>
<td>OR = 1.41, CI 0.88–2.29, <italic>p</italic> = 0.14</td></tr>
<tr>
<td> A/A</td>
<td>25/139 (18%)</td>
<td>39/288 (13.5%)</td>
<td>OR = 1.71, CI 0.88–3.29, <italic>p</italic> = 0.10</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312436858"><label>*</label><p><italic>p</italic>-value&lt;0.05.</p></fn>
<fn id="table-fn2-0961203312436858"><p>SNP: single-nucleotide polymorphisms.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>c.−52G&gt;A frequency distributions were significantly different between SLE patients and healthy subjects. The A allele, at −52 position, was significantly less frequent in SLE patients (36.7%) than healthy controls group (45.8%) (<italic>p</italic> = 0.01), providing protection against SLE (OR = 0.68, CI 0.50–0.92). In agreement with the observed results of the A allele, the frequency of the −52 A/A genotype was also significantly lower in SLE patients (15.8%) than in controls (22.9%) again showing a protective effect (OR = 0.51, CI 0.27–0.94, <italic>p</italic> = 0.02).</p>
<p>c.−44C&gt;G C/G genotype was more frequent in patients (32.4%) than in controls (22.9%), suggesting an increased susceptibility to SLE (OR = 1.60, CI 0.99–2.58, <italic>p</italic> = 0.04). No significant differences in genotype and allele frequencies between patients and controls were observed for the c.−20C&gt;G SNPs.</p>
<p>The three SNPs c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A are in linkage disequilibrium (D’ ≥ 0.87) and combined to form four different haplotypes (<xref ref-type="table" rid="table3-0961203312436858">Table 3</xref>). Statistically significant differences were also found for haplotype distribution, with GCA and GGG occurring more frequently in SLE patients (43.5%, 18.7%) than controls (36.3% and 14.4% respectively). The presence of GCA or GGG haplotypes confers an increased risk for SLE development (OR = 1.51 and OR = 1.63 respectively).
<table-wrap id="table3-0961203312436858" position="float"><label>Table 3</label><caption><p>Haplotypes frequencies of 5’UTR <italic>DEFB1</italic> SNPs (−52G&gt;A/−44C&gt;G/−20G&gt;A) in SLE patients and healthy controls. <italic>P</italic>-values, odds ratio (OR) and 95% confidence intervals (CI) are also reported</p></caption>
<graphic alternate-form-of="table3-0961203312436858" xlink:href="10.1177_0961203312436858-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Haplotypes</th>
<th>SLE patients (<italic>n</italic> = 139)</th>
<th>Healthy controls (<italic>n</italic> = 288)</th>
<th>OR, 95%CI and <italic>p</italic>-values</th></tr></thead>
<tbody align="left">
<tr>
<td>ACG</td>
<td>0.363</td>
<td>0.458</td>
<td>OR = 1</td></tr>
<tr>
<td>GCA</td>
<td>0.435</td>
<td>0.363</td>
<td>OR = 1.51, CI 1.08–2.11, <italic>p</italic> = 0.01<xref ref-type="table-fn" rid="table-fn3-0961203312436858">*</xref></td></tr>
<tr>
<td>GGG</td>
<td>0.187</td>
<td>0.144</td>
<td>OR = 1.63, CI 1.05–2.52, <italic>p</italic> = 0.02<xref ref-type="table-fn" rid="table-fn3-0961203312436858">*</xref></td></tr>
<tr>
<td>GCG</td>
<td>0.011</td>
<td>0.030</td>
<td>OR = 0.46, CI 0.08–1.65, <italic>p</italic> = 0.30</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312436858"><label>*</label><p><italic>p</italic>-value&lt;0.05.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The clinical and laboratory manifestations of SLE patients were also analyzed with respect to 5’UTR <italic>DEFB1</italic> polymorphisms (<xref ref-type="table" rid="table4-0961203312436858">Table 4</xref>). A significant association was observed for c.−52G&gt;A A/G genotype in patients with the neuropsychiatric disorders (61.5%), immunological alterations (57.1%) and antibody anti-DNA (74.1%). The latter were also characterized by an increased frequency of the c.−44C&gt;G G/C genotype (51.9%). Although not statistically significant, the c.−44 C/C genotype was more frequent in antibody antiphospholipid (AAPS) positive patients (60.7%) while the c.−20 G/G in patients with immunological alterations was 50%.
<table-wrap id="table4-0961203312436858" position="float"><label>Table 4</label><caption><p>SLE patients’ clinical manifestations according to patient 5’UTR <italic>DEFB1</italic> genotype. Data are indicated as <italic>n</italic>. of patients and (%). <italic>p</italic>-values are also reported</p></caption>
<graphic alternate-form-of="table4-0961203312436858" xlink:href="10.1177_0961203312436858-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th align="center" colspan="4">−52G&gt;A<hr/></th>
<th align="center" colspan="4">−44C&gt;G<hr/></th>
<th align="center" colspan="4">−20G&gt;A<hr/></th></tr>
<tr><th>Clinical manifestations</th>
<th>A/A</th>
<th>A/G</th>
<th>G/G</th>
<th><italic>p</italic>-value</th>
<th>C/C</th>
<th>G/C</th>
<th>G/G</th>
<th><italic>p</italic>-value</th>
<th>A/A</th>
<th>A/G</th>
<th>G/G</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>Photosensitivity</td>
<td>11 (27.5%)</td>
<td>17 (42.5%)</td>
<td>12 (30%)</td>
<td>0.16</td>
<td>29 (72.5%)</td>
<td>10 (25%)</td>
<td>1 (2.5%)</td>
<td>0.48</td>
<td>6 (15%)</td>
<td>15 (37.5%)</td>
<td>19 (47.5%)</td>
<td>0.67</td></tr>
<tr>
<td>Serositis</td>
<td>6 (17.1%)</td>
<td>19 (54.3%)</td>
<td>10 (28.6%)</td>
<td>0.96</td>
<td>23 (65.7%)</td>
<td>10 (28.6%)</td>
<td>2 (5.7%)</td>
<td>0.44</td>
<td>6 (17.1%)</td>
<td>13 (37.1%)</td>
<td>16 (45.7%)</td>
<td>0.83</td></tr>
<tr>
<td>Arthritis</td>
<td>12 (20.3%)</td>
<td>30 (50.8%)</td>
<td>17 (28.8%)</td>
<td>0.8</td>
<td>39 (66.1%)</td>
<td>19 (32.2%)</td>
<td>1 (1.7%)</td>
<td>0.84</td>
<td>8 (13.6%)</td>
<td>25 (42.4%)</td>
<td>26 (44.1%)</td>
<td>0.84</td></tr>
<tr>
<td>Cutaneous alterations</td>
<td>14 (16.9%)</td>
<td>44 (53%)</td>
<td>25 (30.1%)</td>
<td>0.82</td>
<td>53 (63.9%)</td>
<td>28 (33.7%)</td>
<td>2 (2.4%)</td>
<td>0.84</td>
<td>12 (14.5%)</td>
<td>37 (44.6%)</td>
<td>34 (41%)</td>
<td>0.69</td></tr>
<tr>
<td>Neuropsychiatric disorder</td>
<td>7 (26.9%)</td>
<td>16 (61.5%)</td>
<td>3 (11.5%)</td>
<td>0.03<xref ref-type="table-fn" rid="table-fn4-0961203312436858">*</xref></td>
<td>17 (65.4%)</td>
<td>9 (34.6%)</td>
<td>0 (0%)</td>
<td>1</td>
<td>1 (3.8%)</td>
<td>11 (42.3%)</td>
<td>14 (53.8%)</td>
<td>0.13</td></tr>
<tr>
<td>Nephritic disorder</td>
<td>13 (16.9%)</td>
<td>41 (53.2%)</td>
<td>23 (29.9%)</td>
<td>0.82</td>
<td>51 (66.2%)</td>
<td>24 (31.2%)</td>
<td>2 (2.6%)</td>
<td>0.89</td>
<td>10 (13%)</td>
<td>37 (48.1%)</td>
<td>30 (39%)</td>
<td>0.23</td></tr>
<tr>
<td>Hematological alterations</td>
<td>17 (22.4%)</td>
<td>38 (50%)</td>
<td>21 (27.6%)</td>
<td>0.30</td>
<td>50 (65.8%)</td>
<td>24 (31.6%)</td>
<td>2 (2.6%)</td>
<td>0.94</td>
<td>12 (15.8%)</td>
<td>26 (34.2%)</td>
<td>38 (50%)</td>
<td>0.1</td></tr>
<tr>
<td>Immunological alterations</td>
<td>18 (21.4%)</td>
<td>48 (57.1%)</td>
<td>18 (21.4%)</td>
<td>0.01<xref ref-type="table-fn" rid="table-fn4-0961203312436858">*</xref></td>
<td>57 (67.9%)</td>
<td>24 (28.6%)</td>
<td>3 (3.6%)</td>
<td>0.48</td>
<td>10 (11.9%)</td>
<td>32 (38.1%)</td>
<td>42 (50%)</td>
<td>0.05</td></tr>
<tr>
<td>Antinuclear Factor positive (ANF)</td>
<td>22 (19.8%)</td>
<td>60 (54.1%)</td>
<td>29 (26.1%)</td>
<td>0.05</td>
<td>74 (66.7%)</td>
<td>34 (30.6%)</td>
<td>3 (2.7%)</td>
<td>0.48</td>
<td>15 (13.5%)</td>
<td>46 (41.4%)</td>
<td>50 (45%)</td>
<td>0.25</td></tr>
<tr>
<td>Antibody anti DNA (anti ds-DNA)</td>
<td>2 (7.4%)</td>
<td>20 (74.1%)</td>
<td>5 (18.5%)</td>
<td>0.03<xref ref-type="table-fn" rid="table-fn4-0961203312436858">*</xref></td>
<td>12 (44.4%)</td>
<td>14 (51.9%)</td>
<td>1 (3.7%)</td>
<td>0.04<xref ref-type="table-fn" rid="table-fn4-0961203312436858">*</xref></td>
<td>2 (7.4%)</td>
<td>9 (33.3%)</td>
<td>16 (59.3%)</td>
<td>0.14</td></tr>
<tr>
<td>Antibody antiphospholipid (AAPS)</td>
<td>4 (14.3%)</td>
<td>15 (53.6%)</td>
<td>9 (32.1%)</td>
<td>0.92</td>
<td>17 (60.7%)</td>
<td>8 (28.6%)</td>
<td>3 (10.7%)</td>
<td>0.05</td>
<td>3 (10.7%)</td>
<td>13 (46.4%)</td>
<td>12 (42.9%)</td>
<td>0.74</td></tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>1 (25%)</td>
<td>3 (75%)</td>
<td>0 (0%)</td>
<td>0.39</td>
<td>2 (50%)</td>
<td>2 (50%)</td>
<td>0 (0%)</td>
<td>0.64</td>
<td>0 (0%)</td>
<td>1 (25%)</td>
<td>3 (75%)</td>
<td>0.51</td></tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>2 (28.6%)</td>
<td>2 (28.6%)</td>
<td>3 (42.9%)</td>
<td>0.38</td>
<td>6 (85.7%)</td>
<td>1 (14.3%)</td>
<td>0 (0%)</td>
<td>0.53</td>
<td>2 (28.6%)</td>
<td>2 (28.6%)</td>
<td>3 (42.9%)</td>
<td>0.51</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312436858"><label>*</label><p><italic>p</italic>-value&lt;0.05.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Finally, no significant differences in clinical manifestation were observed in relation to sex or ethnicity.</p></sec>
<sec id="sec7-0961203312436858" sec-type="discussion"><title>Discussion</title>
<p>SLE is a complex autoimmune disease, affecting several organs and human systems. A multifactorial mechanism, encompassing the interaction of genetic, environmental, viral and immunological factors, has been currently purposed,<sup><xref ref-type="bibr" rid="bibr2-0961203312436858">2</xref></sup> although the entire process is not completely understood so far. Moreover, the role of several innate immune components on the onset of SLE has not been described. Defensins are immunomodulatory peptides belonging to the innate immune system, exerting antimicrobial activity and capable of modulating several disease states and the response to inflammatory stimuli.<sup><xref ref-type="bibr" rid="bibr3-0961203312436858">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203312436858">4</xref></sup> Different findings have been suggesting the implication of defensins in the pathogenesis of autoimmune disorder.<sup><xref ref-type="bibr" rid="bibr16-0961203312436858">16</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr22-0961203312436858">22</xref></sup> In our study, we investigated the possible association of three SNPs at positions −52, −44 and −20 in the 5’UTR of <italic>DEFB1</italic> gene (encoding for human β-defensin-1), with the susceptibility and clinical manifestations of SLE.</p>
<p>Our results showed a positive association between −52 A allele and AA genotype with protection from development of SLE (OR = 0.68, <italic>p</italic> = 0.01; OR = 0.51, <italic>p</italic> = 0.02), while on the other hand c.−44C&gt;G C/G genotype was associated with an increased susceptibility to SLE (OR = 1.60, <italic>p</italic> = 0.04). No statistically significant difference was found for the c.−20G&gt;A SNP between patients and healthy controls. In addition, we also found an association between the two haplotypes GCA and GGG and susceptibility towards SLE (OR = 1.51 and OR = 1.63 respectively).</p>
<p>When analyzing the possible association between <italic>DEFB1</italic> SNPs and clinical and laboratory SLE manifestations in patients, an association was observed between the −52 A/G and neuropsychiatric disorders, immunological alterations and anti-DNA antibodies and −44 G/C with anti-DNA antibodies. However, when considering the −52A/G SNP we have to bear in mind that the −52AA genotype conferred protection from SLE development, so the heterozygous −52AG genotype could be considered as a possible marker associated with SLE clinical features, also taking into account that the −52AG heterozygous genotype has a no known relevant functional effect on hBD1 production.</p>
<p>If it’s true that the <italic>p</italic>-values we reported are just within the statistically significant threshold and by applying Bonferroni's correction the statistical significance will be lost, nonetheless, we think that these differences could be indicative of the involvement of the <italic>DEFB1</italic> gene in SLE development and clinical manifestation, especially since the number of samples analyzed, once stratified according to clinical characteristics, is not so big. An acceptable<italic> p</italic>-value threshold for declaring association between a marker and disease is the subject of considerable debate and it is known that applying standard methods of correction for multiple testing such as the Bonferroni's adjustment is thought to be quite conservative and may be overly stringent, possibly failing to recognize single small effects such as those expected by each gene in complex diseases. For this reason we preferred to avoid setting rigorous thresholds in order to highlight possible associations between <italic>DEFB1</italic> and SLE; associations that of course will need to be further investigated and confirmed by other studies as well as in different populations.<sup><xref ref-type="bibr" rid="bibr23-0961203312436858">23</xref></sup></p>
<p>It also has to be acknowledged that, due to the limited number of samples available for the analysis, the power of our study could not have been sufficient to identify some possible small <italic>DEFB1</italic> SNPs effects. In fact, the power of our study, calculated for the association between the different alleles and SLE risk, was ∼80% for the c.−52G&gt;A, ∼40% for the c.−44C&gt;G and ∼50% for the c.−20G&gt;A SNP</p>
<p>An association between polymorphism in the <italic>DEFB1</italic> gene and autoimmune diseases has already been reported,<sup><xref ref-type="bibr" rid="bibr16-0961203312436858">16</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr22-0961203312436858">22</xref></sup> but to our knowledge, no previous studies have investigated the possible association between SLE and <italic>DEFB1</italic> SNPs.</p>
<p>The effect of c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A alleles on <italic>DEFB1</italic> expression is still to be elucidated. An in silico study determined how the 5’UTR <italic>DEFB1</italic> gene affects the mRNA secondary structure and suggests that possibly correlates with translation efficiency in the susceptibility of disease.<sup><xref ref-type="bibr" rid="bibr24-0961203312436858">24</xref></sup> The authors submitted to secondary structure prediction the <italic>DEFB1</italic> exon 1 sequences with all possible haplotypes of c.−52G&gt;A, c.−44C&gt;G and c.−20G&gt;A SNPs and observed the presence of three alternative 5’UTR sizes. The c.−44C&gt;G and c.−20G&gt;A SNPs may spatially interact when found in the longest mRNA, however, −52 SNP alone caused changes to the 5’end structure in intermediate mRNA. This post-transcriptional regulation model may explain the controversial data observed in association studies, where the same allele can be associated with protection or susceptibility.</p>
<p>Previous studies investigated the possible transcriptional effect of the SNPs in <italic>DEFB1</italic> gene 5’ UTR region in vitro.<sup><xref ref-type="bibr" rid="bibr8-0961203312436858">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203312436858">9</xref></sup> Milanese et al.<sup><xref ref-type="bibr" rid="bibr8-0961203312436858">8</xref></sup> observed that the c.−44A&gt;G variation caused a significant reduction (more than 50%) in gene expression, the same way as −52A and −20A alleles caused a relevant, although not significant, reduction of 25% in expression. Controversial results were reported by another study, where the presence of the −44 G allele caused an increase of the promoter activity in the cell lines tested.<sup><xref ref-type="bibr" rid="bibr9-0961203312436858">9</xref></sup> Moreover, Kalus et al.<sup><xref ref-type="bibr" rid="bibr25-0961203312436858">25</xref></sup> demonstrate that the <italic>DEFB1</italic> −44 G allele was associated with increased constitutive expression of both hBD1 and hBD3 mRNA, with increased antimicrobial activity in oral keratinocytes, and with increased reporter protein expression in transfected cells.</p>
<p>In our work, however, we did not evidence any association between the −44 SNP and SLE susceptibility; moreover, when looking at haplotypes, both the GGG and GCA (thus carrying alternatively the G and C alleles at −44) were more frequent in SLE patients than controls<italic>.</italic> In their study, Kreuter et al.<sup><xref ref-type="bibr" rid="bibr26-0961203312436858">26</xref></sup> analyzed the gene and protein expression of several antimicrobial peptides (AMPs) including hBD−1,−2,−3 in patients with cutaneous lupus erythematosus (CLE). Both the human β-defensin-2 and −3 (genes and encoded protein) were significantly more expressed in CLE than controls, suggesting that these defensins can participate in human skin defense. Conversely, hBD-1 showed no differential expression and does not seem to contribute to skin defense in CLE.</p>
<p>Some previous studies reported the association between α-defensin expression and SLE. Tamiya et al.<sup><xref ref-type="bibr" rid="bibr27-0961203312436858">27</xref></sup> observed a significantly increase of seric defensins and cathepsin G-ANCA in SLE patients when compared with controls. A higher titer of autoantibodies in active SLE patients was also detected, suggesting that defensins and cathepsin G-ANCA may serve as markers for disease activity of SLE. In a study using the microarrays technology, the neutrophil-specific alpha 3 defensin (<italic>DEFA3</italic>) was shown to be up-regulated in SLE patients. <italic>DEFA3</italic> is expressed in B and T cells and their altered expression may be a characteristic related to autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr28-0961203312436858">28</xref></sup> Other expression studies also observed an up-regulation of <italic>DEFA3</italic> in active SLE patients.<sup><xref ref-type="bibr" rid="bibr29-0961203312436858">29</xref></sup> All these studies speculated that defensin expression in SLE may have patho-physiological importance by activating both the innate and adaptive immune system, suggesting a role for α-defensins, but not for β-defensin in the pathogenesis of SLE.</p>
<p>In a recent study, Vordenbäumen et al.<sup><xref ref-type="bibr" rid="bibr30-0961203312436858">30</xref></sup> analyzed the expression of hBD2 and human neutrophil peptides (HNP) in serum and blood samples of SLE patients. When the authors compared hBD2 levels between SLE patients and healthy controls they observed elevated hBD2 serum levels in SLE patients, correlating with the disease activity parameters (SLEDAI), anti-dsDNA antibodies, erythrocyte count and myositis. SLE patients with a rash presented elevated serum levels of HNP. hBD2 and HNP expression was not significantly correlated with mRNA variations in the two genes encoding for the antimicrobial peptides). This was the first study that found elevated values of hBD2 in SLE. When considering the above-mentioned studies we can hypothesize that, within the innate immunity mechanisms involved in the susceptibility to SLE, defensins are supposed to play a key role in the modulation of SLE pathogenesis.</p>
<p>Even if the specific role of 5’UTR SNPs in the regulation of <italic>DEFB1</italic> gene expression and the role of the human β-defensin in SLE are still to be elucidated, nonetheless in this study we investigated for the first time the possible association between SNPs in the <italic>DEFB1</italic> gene and susceptibility to SLE: our results support a role for <italic>DEFB1</italic> in SLE development. Additional association studies in other populations, as well as functional studies, are needed to corroborate these findings.</p></sec>
</body>
<back>
<sec id="sec8-0961203312436858"><title>Funding</title>
<p>We acknowledge the financial support of FACEPE/CNPq. LS is recipient of a fellowship grant (APQ-0020-4.01/08) from FACEPE. SC is recipient of a fellowship grant from European Project ‘Talents for an International House’ within the framework of the 7th Research &amp; Development Framework Programme PEOPLE – Marie Curie Actions – COFUND (Co-Funding of Regional, National and International Programmes).</p></sec>
<sec id="sec9-0961203312436858"><title>Conflict of interest</title>
<p>None of the authors has any potential financial conflict of interest related to this manuscript.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312436858"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>929</fpage>–<lpage>939</lpage>.</citation></ref>
<ref id="bibr2-0961203312436858"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sthoeger</surname><given-names>ZM</given-names></name><name><surname>Bezalel</surname><given-names>S</given-names></name><name><surname>Chapnik</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>High alpha-defensin levels in patients with systemic lupus erythematosus</article-title>. <source>Immunology</source> <year>2008</year>; <volume>127</volume>: <fpage>116</fpage>–<lpage>122</lpage>.</citation></ref>
<ref id="bibr3-0961203312436858"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Froy</surname><given-names>O</given-names></name><name><surname>Sthoeger</surname><given-names>ZM</given-names></name></person-group>. <article-title>Defensins in systemic lupus erythematosus</article-title>. <source>Ann N Y Acad Sci</source> <year>2009</year>; <volume>1173</volume>: <fpage>365</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr4-0961203312436858"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>MC</given-names></name></person-group>. <article-title>A protective role for innate immunity in systemic lupus erythematosus</article-title>. <source>Nat Rev Immunol</source> <year>2004</year>; <volume>4</volume>: <fpage>825</fpage>–<lpage>831</lpage>.</citation></ref>
<ref id="bibr5-0961203312436858"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bensch</surname><given-names>KW</given-names></name><name><surname>Raida</surname><given-names>M</given-names></name><name><surname>Magert</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>hBD 1: a novel beta defensin from human plasma</article-title>. <source>FEBS Lett</source> <year>1995</year>; <volume>368</volume>: <fpage>331</fpage>–<lpage>335</lpage>.</citation></ref>
<ref id="bibr6-0961203312436858"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harder</surname><given-names>J</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Mapping of the gene encoding human beta defensin 2 (DEFB2) to chromosome region 8p22–p23.1</article-title>. <source>Genomics</source> <year>1997</year>; <volume>46</volume>: <fpage>472</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr7-0961203312436858"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jurevic</surname><given-names>RJ</given-names></name><name><surname>Chrisman</surname><given-names>P</given-names></name><name><surname>Mancl</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Single-nucleotide polymorphisms and haplotype analysis in beta-defensin genes in different ethnic populations</article-title>. <source>Genet Test</source> <year>2002</year>; <volume>6</volume>: <fpage>261</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr8-0961203312436858"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milanese</surname><given-names>M</given-names></name><name><surname>Segat</surname><given-names>L</given-names></name><name><surname>Crovella</surname><given-names>S</given-names></name></person-group>. <article-title>Transcriptional effect of DEFB1 gene 5' untranslated region polymorphisms</article-title>. <source>Cancer Res</source> <year>2007</year>; <volume>67</volume>: <fpage>5997</fpage>–<lpage>5997</lpage>.</citation></ref>
<ref id="bibr9-0961203312436858"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>CQ</given-names></name><name><surname>Arnold</surname><given-names>R</given-names></name><name><surname>Fernandez-Golarz</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma</article-title>. <source>Cancer Res</source> <year>2006</year>; <volume>66</volume>: <fpage>8542</fpage>–<lpage>8549</lpage>.</citation></ref>
<ref id="bibr10-0961203312436858"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>AE</given-names></name><name><surname>Marrero</surname><given-names>AR</given-names></name><name><surname>Salzano</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Frequency of CCR5delta32 in Brazilian populations</article-title>. <source>Braz J Med Biol Res</source> <year>2006</year>; <volume>39</volume>: <fpage>321</fpage>–<lpage>325</lpage>.</citation></ref>
<ref id="bibr11-0961203312436858"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veit</surname><given-names>TD</given-names></name><name><surname>Cordero</surname><given-names>EA</given-names></name><name><surname>Mucenic</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>424</fpage>–<lpage>430</lpage>.</citation></ref>
<ref id="bibr12-0961203312436858"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braida</surname><given-names>L</given-names></name><name><surname>Boniotto</surname><given-names>M</given-names></name><name><surname>Pontillo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children</article-title>. <source>AIDS</source> <year>2004</year>; <volume>18</volume>: <fpage>1598</fpage>–<lpage>1600</lpage>.</citation></ref>
<ref id="bibr13-0961203312436858"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jurevic</surname><given-names>RJ</given-names></name><name><surname>Bai</surname><given-names>M</given-names></name><name><surname>Chadwick</surname><given-names>RB</given-names></name><etal/></person-group>. <article-title>Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls</article-title>. <source>J Clin Microbiol</source> <year>2003</year>; <volume>41</volume>: <fpage>90</fpage>–<lpage>96</lpage>.</citation></ref>
<ref id="bibr14-0961203312436858"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title>. <source>Bioinformatics</source> <year>2005</year>; <volume>21</volume>: <fpage>263</fpage>–<lpage>265</lpage>.</citation></ref>
<ref id="bibr15-0961203312436858"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group>. <article-title>G.*Power 3: A flexible statistical power analysis for the social, behavioral, and biomedical sciences</article-title>. <source>Behavior Research Methods</source> <year>2007</year>; <volume>39</volume>: <fpage>175</fpage>–<lpage>191</lpage>.</citation></ref>
<ref id="bibr16-0961203312436858"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segat</surname><given-names>L</given-names></name><name><surname>Guimarães</surname><given-names>RL</given-names></name><name><surname>Brandão</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Beta defensin-1 gene (DEFB1) polymorphisms are not associated with atopic dermatitis in children and adolescents from northeast Brazil (Recife, Pernambuco)</article-title>. <source>Int J Dermatol</source> <year>2010</year>; <volume>49</volume>: <fpage>653</fpage>–<lpage>657</lpage>.</citation></ref>
<ref id="bibr17-0961203312436858"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prado-Montes de Oca</surname><given-names>E</given-names></name><name><surname>García-Vargas</surname><given-names>A</given-names></name><name><surname>Lozano-Inocencio</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Association of beta-defensin 1 single nucleotide polymorphisms with atopic dermatitis</article-title>. <source>Int Arch Allergy Immunol</source> <year>2007</year>; <volume>142</volume>: <fpage>211</fpage>–<lpage>218</lpage>.</citation></ref>
<ref id="bibr18-0961203312436858"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Namkung</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Single nucleotide polymorphisms and the haplotype in the DEFB1 gene are associated with atopic dermatitis in a Korean population</article-title>. <source>J Dermatol Sci</source> <year>2009</year>; <volume>54</volume>: <fpage>25</fpage>–<lpage>30</lpage>.</citation></ref>
<ref id="bibr19-0961203312436858"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Raby</surname><given-names>BA</given-names></name><name><surname>Lake</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Association of defensin beta-1 gene polymorphisms with asthma</article-title>. <source>J Allergy Clin Immunol</source> <year>2005</year>; <volume>115</volume>: <fpage>252</fpage>–<lpage>258</lpage>.</citation></ref>
<ref id="bibr20-0961203312436858"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>TF</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Liu</surname><given-names>EK</given-names></name><etal/></person-group>. <article-title>Asthma and atopy are associated with DEFB1 polymorphisms in Chinese children</article-title>. <source>Genes Immun</source> <year>2006</year>; <volume>7</volume>: <fpage>59</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr21-0961203312436858"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milanese</surname><given-names>M</given-names></name><name><surname>Segat</surname><given-names>L</given-names></name><name><surname>Pontillo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children</article-title>. <source>AIDS</source> <year>2006</year>; <volume>20</volume>: <fpage>1673</fpage>–<lpage>1675</lpage>.</citation></ref>
<ref id="bibr22-0961203312436858"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guimarães</surname><given-names>RL</given-names></name><name><surname>Segat</surname><given-names>L</given-names></name><name><surname>Rocha</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Functional polymorphisms of DEFB1 gene in type 1 diabetes Brazilian children</article-title>. <source>Autoimmunity</source> <year>2009</year>; <volume>42</volume>: <fpage>406</fpage>–<lpage>413</lpage>.</citation></ref>
<ref id="bibr23-0961203312436858"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name></person-group>. <article-title>Association study designs for complex diseases</article-title>. <source>Nat Rev Genet</source> <year>2001</year>; <volume>2</volume>: <fpage>91</fpage>–<lpage>99</lpage>.</citation></ref>
<ref id="bibr24-0961203312436858"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naslavsky</surname><given-names>MS</given-names></name><name><surname>Crovella</surname><given-names>S</given-names></name><name><surname>Lima Filho</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>The sound of silence: human beta-defensin-1 gene untranslated SNPs change the predicted mRNA secondary structure in a length-dependent manner</article-title>. <source>Immunol Lett</source> <year>2010</year>; <volume>129</volume>: <fpage>53</fpage>–<lpage>55</lpage>.</citation></ref>
<ref id="bibr25-0961203312436858"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalus</surname><given-names>AA</given-names></name><name><surname>Fredericks</surname><given-names>LP</given-names></name><name><surname>Hacker</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Association of a genetic polymorphism (−44 C/G SNP) in the human DEFB1 gene with expression and inducibility of multiple beta-defensins in gingival keratinocytes</article-title>. <source>BMC Oral Health</source> <year>2009</year>; <volume>27</volume>: <fpage>9</fpage>–<lpage>21</lpage>.</citation></ref>
<ref id="bibr26-0961203312436858"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Jaouhar</surname><given-names>M</given-names></name><name><surname>Skrygan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus</article-title>. <source>J Am Acad Dermatol</source> <year>2011</year>; <volume>65</volume>: <fpage>125</fpage>–<lpage>133</lpage>.</citation></ref>
<ref id="bibr27-0961203312436858"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamiya</surname><given-names>H</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Miyata</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Defensins- and cathepsin G-ANCA in systemic lupus erythematosus</article-title>. <source>Rheumatol Int</source> <year>2006</year>; <volume>27</volume>: <fpage>147</fpage>–<lpage>152</lpage>.</citation></ref>
<ref id="bibr28-0961203312436858"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Onda</surname><given-names>H</given-names></name><name><surname>Tanigawa</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients</article-title>. <source>DNA Res</source> <year>2005</year>; <volume>12</volume>: <fpage>429</fpage>–<lpage>439</lpage>.</citation></ref>
<ref id="bibr29-0961203312436858"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>L</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Arce</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Interferon and granulopoiesis signatures in systemic lupus erythematosus blood</article-title>. <source>J Exp Med</source> <year>2003</year>; <volume>197</volume>: <fpage>711</fpage>–<lpage>723</lpage>.</citation></ref>
<ref id="bibr30-0961203312436858"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vordenbäumen</surname><given-names>S</given-names></name><name><surname>Fischer-Betz</surname><given-names>R</given-names></name><name><surname>Timm</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Elevated levels of human beta-defensin 2 and human neutrophil peptides in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1648</fpage>–<lpage>1653</lpage>.</citation></ref>
</ref-list>
</back>
</article>